ACS Medicinal Chemistry Letters · 2012 · 18 citations · 17 references
MedicineMedicinal ChemistryPharmacologyNeuropharmacologyPharmacodynamicsPsychopharmacologyAntidepressant PharmacologyAntidepressant PharmacotherapyAntidepressant TherapyOpioid AnalgesicsOpioid PharmacologySerotonergic Pharmacology5-Hydroxytryptamine Receptor PharmacologyAdrenergic Receptor AntagonistsAlpha-2 AgonistsAntidepressant EfficacyAntidepressant ResponseNaloxone Withdrawal SyndromeSerotonin AgonistsWithdrawal Symptoms
This study demonstrated that cyclomethyline (2) and the corresponding enantiomers (R)-(-)-2 and (S)-(+)-2, displaying α2C-adrenoreceptor (AR) agonism/α2A-AR antagonism, similarly to allyphenyline (1) and its enantiomers, significantly decreased the naloxone-precipitated withdrawal symptoms in mice at very low doses. It also highlighted that such positive effects on morphine dependence can even be improved by additional serotoninergic 5-HT1A receptor (5-HT1A-R) activation. Indeed, 1 or the single (S)-(+)-1, 2, or both its enantiomers, all behaving as α2C-AR agonists/α2A-AR antagonists/5-HT1A-R agonists, alone and at the same low dose, improved morphine withdrawal syndrome and exerted a potent antidepressant-like effect. Therefore, considering the elevated comorbidity between opiate abuse and depressed mood and the benefit of these multifunctional compounds to both disorders, it is possible that they prove more efficacious and less toxic than a cocktail of drugs in managing opioid addiction.
17
Raymond Mongeau, Pierre Blier, Claude de Montigny · Naunyn-Schmiedeberg s Archives of Pharmacology · 1993 · 105 citations
Ian A. Cliffe, Christopher I. Brightwell, Allan Fletcher et al. · Journal of Medicinal Chemistry · 1993 · 81 citations · Full text
Medicine, Neuroscience, Pharmacology +14